FDA Okays First Generics for Eliquis (Apixaban)
The FDA has approved two applications for the first generic versions of apixaban to reduce stroke and systemic embolism for patients with atrial fibrillation.
Related Articles
Muscle Gains vs Heart Strain: A Deadly Trade-off?
Experts say intense workouts, extreme diets, aggressive dehydration, and doping are likely to interact to elevate cardiovascular risk in competitive bodybuilders.
Cannabis Hard on the Heart and Doubles Risk for CVD Death, Major Study Shows
Cannabis users have significantly higher risks for dying from cardiovascular disease, according to a sweeping new study, prompting experts to call for tobacco-style regulation.
Cannabis Hard on the Heart and Doubles Risk for CVD Death, Major Study Shows
Cannabis users have significantly higher risks for dying from cardiovascular disease, according to a sweeping new study, prompting experts to call for tobacco-style regulation.
Should Adults Update Their Measles Vaccinations?
Despite recent outbreaks, most adults who were vaccinated as children or previously in adulthood remain at low risk.
The Empathy Surgeons Often Forget at the Bedside
Communicating the need for urgent surgery is never easy. A Virginia-based surgeon offers tips for clearer, more compassionate conversations with patients and families.
Intensive Bevacizumab Boosts Vision in Macular Degeneration
Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a…
Next-Generation Obesity Treatments Take Center Stage at ADA
Research symposia focus on new combinations and medication formulations for both obesity and type 2 diabetes, as well as new approaches for type 1 diabetes…
Medicare Advantage Plans: Where’s the Advantage?
Many Medicare Advantage plans are not delivering better, more efficient care than traditional Medicare, and they need more oversight and accountability, Madelaine A. Feldman, MD,…
Medscape
Transforming Gastric and GEJ Cancer Care With Perioperative Immunotherapy: Latest Updates From Chicago